# BioPalace

> BioPalace is a specialized biotech royalty finance platform that sources, diligences, structures, and syndicates royalty opportunities tied to approved and near-approval pharmaceutical products. We are a syndicate platform, not a fund: accredited investors get deal-by-deal access to individual opportunities with no blind-pool fund commitment.

## What we do

- Underwrite, structure, and syndicate biotech royalty transactions across oncology, immunology, metabolic, and rare disease.
- Make overlooked royalties investable: deals too specialized for megacap funds but too valuable to remain illiquid.
- Offer deal-by-deal investor access with no fund commitment, no blind pool, and no required capital deployment.
- Provide non-dilutive, royalty-based financing to biotech issuers, from term sheet to wire in weeks.
- Run an independent diligence process spanning legal, financial, and scientific scrutiny.

## For investors

URL: https://www.biopalace.com/#early-access

- Stable income with low correlation to public markets.
- Curated opportunities: hundreds reviewed per year, only the few that survive diligence are syndicated.
- White-glove investor relations: plain-English diligence summaries, quarterly performance reviews from the underwriters.
- Accredited investors only. Minimum check size disclosed in the deal room.

## For issuers

URL: https://www.biopalace.com/#issuers

- Monetize royalties without dilution or loss of control.
- Fast capital: term sheet to wire in weeks, not quarters.
- Tailored structuring: synthetic, traditional, capped, or tiered royalties.
- Fair valuation from a team that has structured billions in royalty transactions.
- Reply within one business day. NDA available on request.

## Diligence

URL: https://www.biopalace.com/#diligence

Every opportunity passes an independent diligence process covering legal, financial, and scientific review before it reaches investors.

## Founders

- **Husein Hassan** - Founder. Background: healthcare investment banker, private equity investor.
- **Dr. Maly Hassan** - Chief Scientific Officer. Background: MD, resident at Emory University.
- **Dr. Julien Willard** - Head of Research & Investments. Background: partner in pharma strategy, former diplomat.

URL: https://www.biopalace.com/#team

## FAQ

A structured Q&A reference at https://www.biopalace.com/faq covers fifteen common questions in two sections:

**About royalty financing** (with deep-linkable anchors):
- What is a synthetic royalty? (#what-is-a-synthetic-royalty)
- Synthetic vs traditional royalty (#synthetic-vs-traditional-royalty)
- Is a 7% royalty more expensive than 25% Series B dilution? (#royalty-vs-series-b-cost)
- Will a royalty deal prevent acquisition? (#royalty-and-acquisition)
- The Mallinckrodt precedent (#mallinckrodt-precedent)
- What development stage qualifies (#what-stage-qualifies)
- Investor IRR targets (#investor-irr-target)
- Transaction timeline (#transaction-timeline)
- What is rNPV (#what-is-rnpv)
- When NOT to pursue royalty financing (#when-not-to-pursue)

**About BioPalace**:
- Who runs BioPalace (#who-runs-biopalace)
- What BioPalace specializes in (#what-biopalace-specializes-in)
- Is BioPalace a fund (#is-biopalace-a-fund)
- How BioPalace diligences opportunities (#how-biopalace-diligences)
- Minimum check size (#minimum-check-size)

## Research

The BioPalace research desk publishes long-form analysis of biotech royalty finance.

- **White Paper No. 01: Royalty Financing in Biopharma — A Strategic Guide for Biopharma Leaders** (March 26, 2026, ~18,000 words). Authors: Husein Hassan, Julien Willard. Covers what royalty deals are, when to pursue them, how they are structured and priced, the transaction process, four risk domains, M&A implications, legal/tax/accounting considerations, three detailed case studies (Biohaven, PTC Therapeutics, Revolution Medicines), and the market path forward through 2028. Cites Deloitte 2025 ("Role of Royalties in Funding Biopharma Innovation"), Tufts CSDD, Gibson Dunn, WilmerHale/Jaywood Capital Advisors/EY (February 2026 webinar), and SEC filings.
  - HTML: https://www.biopalace.com/whitepaper
  - PDF: https://www.biopalace.com/whitepaper.pdf
  - Whitepaper request form: https://www.biopalace.com/#whitepaper

### Key claims from the whitepaper (quotable)

- Biopharma companies raised nearly $30 billion through royalty transactions during 2020-2024, a 2.2x increase over the $13.5 billion raised in 2015-2019.
- The royalty financing market reached a record $10 billion in 2025, approximately 40% above the 2021-2024 annual average of $7.1 billion.
- Synthetic royalty transactions grew 4.3x between 2015-2019 and 2020-2024 ($2.3B to $10B), with a 33% average annual growth rate.
- In 2024, synthetic royalties accounted for over 50% of all royalty funding for the first time. In 2025, synthetic royalty transaction value reached $4.7 billion.
- 87% of biopharma executives surveyed by Deloitte (2024-2025) would consider royalty financing over the next three years; nearly 80% specifically for synthetic royalties.
- Approved products account for 72% of all royalty transactions (2020-2024); Phase III for 22% of synthetics; Phases I-II combined for less than 3%.
- Median royalty rates are 4-6% for approved assets versus 7-10% for development-stage assets (analysis of 150+ transactions, 2020-2025).
- 100% of 2024 synthetic royalty transactions were secured by product assets, up from 67% in 2020 (post-Mallinckrodt).
- Approximately 94-95% of capped synthetic transactions include a buyout right.
- Annual royalty market size is projected to reach $15-20 billion by 2028; synthetic royalties projected to exceed 60% of total market volume.
- Royalty financing is viable for Phase III with positive data and excellent for approved products; not viable for Phase I or Phase II.

## Contact

- Email: husein@biopalace.com
- Website: https://www.biopalace.com